Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM.

Br J Cancer. 2004 Oct 18;91(8):1425-7.

2.

Intermittent chemotherapy in metastatic androgen-independent prostate cancer.

Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM.

Br J Cancer. 2003 Sep 15;89(6):968-70.

3.

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.

Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Chi KN, Young J, Henner WD; ASCENT(AIPC Study of Calcitriol ENhancing Taxotere) Investigators..

Cancer. 2008 Jan 15;112(2):326-30.

4.

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD.

J Clin Oncol. 2003 Jan 1;21(1):123-8.

PMID:
12506180
5.

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.

Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.

Urology. 2005 Jan;65(1):126-30.

PMID:
15667877
6.

High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.

Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM.

J Urol. 2005 Sep;174(3):888-92.

PMID:
16093981
7.

Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.

Sella A, Sternberg CN, Skoneczna I, Kovel S.

BJU Int. 2008 Dec;102(11):1607-9. doi: 10.1111/j.1464-410X.2008.07873.x. Epub 2008 Oct 2.

8.

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.

Sinibaldi VJ, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M, Eisenberger MA.

Cancer. 2002 Mar 1;94(5):1457-65.

9.

[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].

Olbert PJ, Weil C, Hegele A, Hofmann R, Schrader AJ.

Aktuelle Urol. 2009 May;40(3):164-8. doi: 10.1055/s-0028-1098888. Epub 2009 Apr 15. German.

PMID:
19370533
10.

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.

Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.

PMID:
19249153
11.

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB.

BMC Cancer. 2007 Jul 27;7:142.

12.

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.

Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.

J Clin Oncol. 2004 Jul 1;22(13):2532-9.

PMID:
15226321
13.

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.

Carles J, Font A, Mellado B, Domenech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM.

Br J Cancer. 2007 Nov 5;97(9):1206-10. Epub 2007 Oct 23.

14.

No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.

Anticancer Res. 2012 Aug;32(8):3305-9.

PMID:
22843906
15.

Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.

Sella A, Sternberg C, Kovel S, Yarom N, Skoneczna I.

BJU Int. 2007 Sep;100(3):533-5. Epub 2007 Jun 8.

16.

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.

El Halim Mohamed Abu Hamar A, Mansour S, El Shebiney M, El Bary NM, Sadaka E, Maria A.

Hematol Oncol Stem Cell Ther. 2010;3(3):121-7.

17.

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.

BJU Int. 2010 Oct;106(7):974-8. doi: 10.1111/j.1464-410X.2010.09296.x. Epub 2010 Mar 9.

18.

Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.

Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R.

Tumori. 2010 Jan-Feb;96(1):48-53.

20.

Docetaxel in combination with prednisolone for hormone refractory prostate cancer.

Ide H, Kikuchi E, Kono H, Nagata H, Miyajima A, Nakagawa K, Ohigashi T, Nakashima J, Oya M.

Jpn J Clin Oncol. 2010 Jan;40(1):79-84. doi: 10.1093/jjco/hyp126. Epub 2009 Oct 16.

PMID:
19837689

Supplemental Content

Support Center